Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: hmpa who wrote (848)	11/6/2003 10:21:26 AM
From: tuck	Read Replies (1) \| Respond to of 1005

BLUE HP hasn't owned GNVC in a while, but the manager's Mom still does . . . >>8:51AM Genvec started with a Buy at Needham; target $7 (GNVC) 3.68: Needham initiates coverage with a Buy rating and $7 target; firm views GNVC as undervalued vs peers in protein therapeutics, and notes that the co has 3 unpartnered clinical products for cancer, ophthalmologic, and cardiovascular diseases; although the co's products are not expected to be on the mkt until 2007, firm believes there are a number of upcoming events over the next 6-12 months to drive investor interest.<< Cheers, Tuck